{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:40:58Z","timestamp":1792633258862,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.msard.2019.101923","type":"journal-article","created":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T21:50:43Z","timestamp":1578261043000},"page":"101923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Cryptococcus neoformans var grubii meningoencephalitis in a patient on fingolimod for relapsing-remitting multiple sclerosis: Case report and review of published cases"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-7600","authenticated-orcid":false,"given":"SB","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DWJ","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SC","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CC","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JSJ","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SD","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.msard.2019.101923_bib0001","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaneurol.2015.1746","article-title":"Cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod","volume":"72","author":"Achtnichts","year":"2015","journal-title":"JAMA Neurol."},{"issue":"12","key":"10.1016\/j.msard.2019.101923_bib0002","first-page":"8","article-title":"Refractory cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod: a case report","volume":"1","author":"Anene-Maidoh","year":"2018","journal-title":"NInterdiscip. Neurosurg."},{"issue":"6","key":"10.1016\/j.msard.2019.101923_bib0003","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2019.101923_bib0004","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1352458516670732","article-title":"Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: here come the opportunistic infections?","volume":"23","author":"Carpenter","year":"2017","journal-title":"Mult Scler."},{"key":"10.1016\/j.msard.2019.101923_bib0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinimag.2018.11.005","article-title":"Cryptococcal meningitis in a multiple sclerosis patient treated with fingolimod: a case report and review of imaging findings","volume":"54","author":"Chong","year":"2019","journal-title":"Clin. Imaging"},{"issue":"3","key":"10.1016\/j.msard.2019.101923_bib0006","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jamaneurol.2015.4259","article-title":"Primary cutaneous cryptococcus in a patient with multiple sclerosis treated with fingolimod","volume":"73","author":"Forrestel","year":"2016","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.msard.2019.101923_bib0007","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/1352458513500551","article-title":"Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy","volume":"20","author":"Francis","year":"2014","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2019.101923_bib0008","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760180060","article-title":"Variability in innate host immune responses to cryptococcosis","volume":"113","author":"Garelnabi","year":"2018","journal-title":"Mem. Inst. Oswaldo. Cruz"},{"key":"10.1016\/j.msard.2019.101923_bib0009","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.msard.2016.07.015","article-title":"Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: a case report and review of literature","volume":"9","author":"Grebenciucova","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1\u20132","key":"10.1016\/j.msard.2019.101923_bib0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","article-title":"Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy","volume":"328","author":"Groves","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"11","key":"10.1016\/j.msard.2019.101923_bib0011","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1212\/WNL.0000000000001929","article-title":"Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod","volume":"85","author":"Huang","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2019.101923_bib0012","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2019.101923_bib0013","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrmicro.2015.6","article-title":"Cryptococcus: from environmental saprophyte to global pathogen","volume":"14","author":"May","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"issue":"2","key":"10.1016\/j.msard.2019.101923_bib0014","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s40588-017-0064-8","article-title":"Cryptococcosis today: it is not all about HIV infection","volume":"4","author":"O'Halloran","year":"2017","journal-title":"Curr. Clin. Microbiol. Rep."},{"issue":"3","key":"10.1016\/j.msard.2019.101923_bib0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.msard.2019.101923_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-220026","article-title":"Cryptococcal meningitis causing obstructive hydrocephalus in a patient on fingolimod","author":"Pham","year":"2017","journal-title":"BMJ Case Rep."},{"issue":"8","key":"10.1016\/j.msard.2019.101923_bib0017","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis","volume":"17","author":"Rajasingham","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.msard.2019.101923_bib0018","article-title":"Fingolimod and cryptococcosis: collision of immunomodulation with infectious disease","author":"Samudralwar","year":"2019","journal-title":"Int. J. MS Care"},{"issue":"22","key":"10.1016\/j.msard.2019.101923_bib0019","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.2169\/internalmedicine.55.7255","article-title":"Disseminated cryptococcosis in a 63-year-old patient with multiple sclerosis treated with fingolimod","volume":"55","author":"Seto","year":"2016","journal-title":"Intern. Med."},{"key":"10.1016\/j.msard.2019.101923_bib0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.msard.2016.06.007","article-title":"Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis","volume":"9","author":"Ward","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2019.101923_bib0021","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1473-3099(17)30245-1","article-title":"The relentless march of cryptococcal meningitis","volume":"17","author":"Williamson","year":"2017","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.msard.2019.101923_bib0022","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","article-title":"Disease-modifying therapies and infectious risks in multiple sclerosis","volume":"12","author":"Winkelmann","year":"2016","journal-title":"Nat. Rev. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819309940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819309940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:49:36Z","timestamp":1761900576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819309940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":22,"alternative-id":["S2211034819309940"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.101923","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cryptococcus neoformans var grubii meningoencephalitis in a patient on fingolimod for relapsing-remitting multiple sclerosis: Case report and review of published cases","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.101923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101923"}}